|Day Low/High||2.46 / 2.62|
|52 Wk Low/High||2.25 / 3.89|
The sum of the company's parts won't get shareholders their rightful value.
CEO Steve Ballmer called talk that the software giant was shopping for a stake 'idle speculation.'
PDL BioPharma jumped after saying its CEO left and it said it was exploring a sale.
Rumors that the superinvestor and banks in Europe and China are eying a stake boosted the stock.
Take a shot at winning a copy of Jim Cramer's latest book!
The activist hedge fund inks a letter calling for the departure of the company's chairman.
It will refocus on cancer and select immunological diseases and unload its Cardene, Retavase and IV Busulfex products.
A relative day of calm in the stock market is offset by wild times in Treasuries. John Roque of Natexis Bleichroeder and Chris Edmonds of ERC lend insights.
Health care stocks are flat, despite nice gains from Enzon and PDL BioPharma.
Mark McDade, long a target of major investor Third Point, is leaving. Is a sale far behind?
Mark McDade, long a target of investor Third Point, will leave the drug company by the end of the year.
The surgical-robotics maker hit a 52-week high on heavy trading after an earnings blowout.
As tattooed baby boomers express regret, these stocks should clean up.
Could Biogen Idec buy PDL BioPharma?;TNFerade doesn't spark confidence; YM BioSciences' nimotuzumab may be for real.
MedcoHealth Solutions moves higher on news of a federal contract.
Celgene climbs on positive data for its oral anti-inflammatory agent.
The company loses a key patent battle. Meanwhile, issues loom with its pipeline.
Check out the stocks that Jim has been talking about lately.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.